Nathan T. James

Nathan T. James

Auto-generated profile, based on publicly available information

Nathan T. James

Department of Biostatistics Vanderbilt University Medical Center Nashville TN USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NJNathan T. James
Nathan T. James
JBJoseph H. Breeyear
Joseph H. Breeyear
RCRichard Caprioli
Richard Caprioli
TETodd Edwards
Todd Edwards
BHBrian Hachey
Brian Hachey
LCLeen Choi
Leen Choi

18 March 2021 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
EMElizabeth McNeer
Elizabeth McNeer
CBCole Beck
Cole Beck
HWHannah L Weeks
Hannah L Weeks
MWMichael L Williams
Michael L Williams
NJNathan T James
Nathan T James
LCLeen Choi
Leen Choi
Objective: To develop an algorithm for building longitudinal medication dose datasets using information extracted from clinical notes in electronic health records (EHRs). Materials and Methods: We developed an algorithm that converts medication information extracted using natural language processing (NLP) into a usable format and builds longitudinal medication dose datasets. We evaluated the algorithm on 2 medications extracted from clinical notes of Vanderbilt’s EHR and externally validated the algorithm using clinical notes from the MIMIC-III clinical care database. Results: For the evaluation using Vanderbilt’s EHR data, the performance of our algorithm was excellent; F1-measures were ≥0.98 for both dose intake and daily dose. For the external validation using MIMIC-III, the algorithm achieved F1-measures ≥0.85 for dose intake and ≥0.82 for daily dose. Discussion: Our algorithm addresses the challenge of building longitudinal medication dose data using information extracted from clinical notes. Overall performance was excellent, but the algorithm can perform poorly when incorrect information is extracted by NLP systems. Although it performed reasonably well when applied to the external data source, its performance was worse due to differences in the way the drug information was written. The algorithm is implemented in the R package, “EHR,” and the extracted data from Vanderbilt’s EHRs along with the gold standards are provided so that users can reproduce the results and help improve the algorithm. Conclusion: Our algorithm for building longitudinal dose data provides a straightforward way to use EHR data for medication-based studies. The external validation results suggest its potential for applicability to other systems.

20 October 2017
Verified
Dataset
Closed access
LCLeen Choi
Leen Choi
CBCole Beck
Cole Beck
HWHannah Weeks
Hannah Weeks
EMElizabeth McNeer
Elizabeth McNeer
NJNathan James
Nathan James
MWMichael Williams
Michael Williams

6 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
NJNathan T. James
Nathan T. James
JBJoseph H. Breeyear
Joseph H. Breeyear
RCRichard Caprioli
Richard Caprioli
TETodd Edwards
Todd Edwards
BHBrian Hachey
Brian Hachey
LCLeen Choi
Leen Choi
Aim: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and data from electronic health records (EHRs) and explore the impact of patient’s characteristics and pharmacogenetics on dexmedetomidine clearance. Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed-effects modeling. The first stage developed a model without genotype variables; the second stage added pharmacogenetic effects. Results: Our final study population included 354 post-cardiac surgery patients age 0 to 22 years (median 16 months). The final two-compartment model included allometric weight scaling and age maturation. Population parameter estimates and 95% confidence intervals were 27.3 L/hr (24.0 – 31.1 L/hr) for total clearance (CL), 161 L (139 – 187 L) for central compartment volume of distribution (V 1 ), 26.0 L/hr (22.5 – 30.0 L/hr) for intercompartmental clearance (Q), and 7903 L (5617 – 11119 L) for peripheral compartment volume of distribution (V 2 ). The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5 – 42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99 – 7.08). Genotype was not statistically or clinically significant. Conclusion: Our study demonstrates the use of real-world EHR data and remnant specimens to perform a population PK analysis and investigate covariate effects in a large pediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score. What is already known about this subject: ∘ Previous dexmedetomidine pharmacokinetic (PK) studies in pediatric populations have limited sample size. ∘ Smaller studies present a challenge for identifying covariates that may impact individual PK profiles. What this study adds: ∘ We performed a dexmedetomidine population PK study with a large pediatric cohort using data obtained from electronic health records and remnant plasma specimens to enable increased sample size. ∘ xsDifferences in PK due to UGT1A4 or UGT2B10 variants or CYP2A6 risk score are not clinically impactful for this population.